Pharmacyclics (PCYC +5.7%) continues where it left off in June, when it surged 74% on the...

|By:, SA News Editor

Pharmacyclics (PCYC +5.7%) continues where it left off in June, when it surged 74% on the prospects for its ibrutinib treatment for chronic lymphocytic leukemia. The stock has quintupled over the past year. Last month was generally a good one for biotechs, with seven gaining over 40%.